WO2020130035A1 - Composition topique moussante - Google Patents

Composition topique moussante Download PDF

Info

Publication number
WO2020130035A1
WO2020130035A1 PCT/JP2019/049587 JP2019049587W WO2020130035A1 WO 2020130035 A1 WO2020130035 A1 WO 2020130035A1 JP 2019049587 W JP2019049587 W JP 2019049587W WO 2020130035 A1 WO2020130035 A1 WO 2020130035A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
composition
foam
active ingredient
weight
Prior art date
Application number
PCT/JP2019/049587
Other languages
English (en)
Japanese (ja)
Inventor
強志 桑原
駿介 加茂
Original Assignee
日東メディック株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71100860&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2020130035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 日東メディック株式会社 filed Critical 日東メディック株式会社
Priority to JP2020526043A priority Critical patent/JP6781358B1/ja
Priority to KR1020217007588A priority patent/KR102584365B1/ko
Priority to CN201980083678.1A priority patent/CN113164511A/zh
Publication of WO2020130035A1 publication Critical patent/WO2020130035A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Definitions

  • the present invention relates to a composition for external use that forms a foam during use.
  • a surfactant is known as a component that forms bubbles.
  • Anionic surfactants are said to have high foaming power but are irritating, and nonionic surfactants are said to have low irritation but low foaming power. No satisfactory foaming power and safety have been obtained.
  • To form a safe and good foam by combining polyoxyethylene alkyl ether and/or polyoxyethylene alkenyl ether as a nonionic surfactant with polyoxyethylene fatty acid ester and/or polyoxyethylene hydrogenated castor oil It is reported that this can be done (Patent Document 1).
  • the amount of the additive is small, and with the smaller amount of the additive, it is possible to produce a foam having a better foam quality, an appropriate foam-holding feeling without dropping, and a foam having a good feeling in use.
  • foamable external compositions There is a strong demand for the development of new foamable external compositions.
  • An object of the present invention is to provide a foamable external composition capable of producing a foam having a better foam quality, an appropriate foam-holding feeling without dropping, and a foam having a good feeling in use.
  • the present inventors have conducted intensive studies in view of such a situation, and have found that the use of a polymer surfactant as a foaming agent achieves a desired purpose. That is, the present invention relates to a composition for external use, which contains a polymeric surfactant as a foaming component and forms foam when used.
  • the formulation of the present invention makes it possible to obtain a new topical composition having a better foam quality, a suitable foam-holding feeling without sagging, and a good feeling of use, particularly gas.
  • a pump former container and a squeeze former container that are not required, it can be used as a non-gas type formulation that exhibits a foamy state at the time of discharge, and a composition suitable for the treatment of skin diseases such as atopic dermatitis can be obtained.
  • Example 3 is a photograph showing the result (foam formation) of Example 1.
  • 5 is a photograph showing the results of Example 2 (foam persistence (evaluated by polyurethane)).
  • 5 is a photograph showing the results of Example 2 (foam persistence (evaluated with Kim towel)).
  • 5 is a photograph showing the result of Example 2 (drip of foam).
  • the external composition of the present invention can be used as a spray agent for foaming a stock solution into a foam at the time of use, or a base thereof.
  • the stock solution means a liquid composition capable of foaming.
  • the composition for external use of the present invention can be used in a foam discharge container in which a stock solution in a container is sprayed by a pump without using a propellant.
  • the foam discharge container is not particularly limited as long as the composition of the present invention can be mixed with air and discharged in a foamed state, and examples thereof include a pump spray (pump former) container that discharges from a pressure pump and a soft container.
  • a squeeze former container or the like that presses the body and discharges is preferably used.
  • the polymer surfactant of the present invention includes ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose (hypromellose), carboxymethyl cellulose, sodium carboxymethyl cellulose, cellulose derivatives such as carboxymethyl ethyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene. At least one selected from glycol and polyacrylic acid.
  • At least one selected, especially hydroxypropylmethyl cellulose (hypromellose) is preferable.
  • hypromellose those having a substitution degree type of 2906 or 2910 stipulated in the Japanese Pharmacopoeia are preferably used.
  • the polymeric surfactant is 0.01 to 10% by weight, preferably 0.1 to 5% by weight, more preferably 0.2 to 3% by weight, particularly about 0.5% by weight, based on the total amount of the composition. , About 0.75% by weight or about 1% by weight.
  • a numerical value is “about”, it includes ⁇ 20%, or ⁇ 10% or ⁇ 5% of the indicated numerical value. According to the present invention, a desired effect can be achieved with only one type of polymeric surfactant.
  • composition of the present invention in addition to the above-mentioned polymer surfactant, if desired, other surfactants that can be used in the fields of pharmaceuticals and cosmetics, such as anionic surfactants, cationic surfactants and amphoteric surfactants. Agents and nonionic surfactants may be added.
  • anionic surfactant for example, N-acyl-N-methylglycine salt, sodium alkylsulfonate, sodium alkyl sulfate, polyoxyethylene alkyl ether carboxylate, sodium lauryl sulfate, etc.
  • a cationic surfactant for example, benzalkonium chloride, benzethonium chloride, an aliphatic amine salt, an aliphatic quaternary ammonium salt, and the like
  • amphoteric surfactant for example, lauryldimethylaminoacetic acid betaine, stearyldimethylaminoacetic acid betaine, 2-alkyl-N.
  • nonionic surfactants such as polyoxyethylene alkyl Ether, polyoxyethylene alkenyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid glyceryl, polyoxypropylene polyoxyethylene alkyl ether and polyoxypropylene polyoxyethylene alkenyl Examples thereof include ether.
  • the composition of the present invention may include alcohol.
  • alcohols include monohydric alcohols such as ethanol and isopropyl alcohol, polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene glycol, dipropylene glycol, diglycerin, isoprene glycol, 1, Examples are polyhydric alcohols such as 2-pentanediol, 2,4-hexanediol, 1,2-hexanediol, and 1,2-octanediol, which may be contained alone or in combination of two or more. Glycerin, propylene glycol, polyethylene glycol and 1,3-butylene glycol are particularly preferred.
  • the total content of the alcohol is 5 to 60% by weight, preferably 10 to 50% by weight, more preferably 15 to 40% by weight.
  • the composition of the present invention preferably has a pH value in the range of 3-12. A more preferable pH value is 4-10.
  • the pH adjuster for adjusting the pH value of the composition to the above range include potassium dihydrogen phosphate, citric acid, etc., and in the high pH range. Those used for adjustment include sodium hydroxide, potassium hydroxide, sodium lactate, sodium citrate, L-arginine, diisopropanolamine and the like.
  • Particularly preferred pH adjusters include potassium dihydrogen phosphate, potassium hydroxide, sodium citrate, citric acid, diisopropanolamine, sodium edetate and the like.
  • liquid composition according to the present invention in addition to the above components, a preservative (preservative), an antioxidant, a wetting agent, a stabilizer, an ultraviolet absorber, etc., which are commonly used in external preparations for skin. Agents can be included.
  • Examples of the above preservative include methyl paraoxybenzoate, ethyl paraoxybenzoate, paraoxybenzoic acid esters (parabens) such as propyl paraoxybenzoate, sodium benzoate, and phenoxyethanol.
  • the above preservatives may be used alone or in combination of two or more.
  • the content of the preservative in the composition is preferably 0.01 to 1% by weight, more preferably 0.1 to 0.5% by weight.
  • composition of the present invention may be provided as a base for producing a drug or cosmetic by incorporating a pharmaceutically active ingredient or an ingredient effective as a cosmetic, and the composition of the present invention contains the pharmaceutically active ingredient. You can leave.
  • a composition containing a pharmaceutically active ingredient is also an aspect of the present invention.
  • composition of the present invention is used as an external preparation applied to the skin to treat skin inflammation, eczema, atopic dermatitis, psoriasis, acne, scars, pressure ulcers, acne and the like (healing, improvement of symptoms, It is preferably applied to skin diseases such as prevention of deterioration and prevention of onset) and also to hair parts such as the scalp as well as the skin.
  • the active ingredient contained in the composition of the present invention is not particularly limited as long as it is applied to the skin and provided, but steroids, nonsteroidal anti-inflammatory agents, bactericides, antibacterial agents, antifungals. Examples include agents, vitamins, immunosuppressants, mucopolysaccharides, cAMP derivatives, fibroblast growth factors, naphthoic acid derivatives, benzoyl peroxide and the like.
  • the steroids are not particularly limited as long as they have a steroid skeleton, but include cortisone, hydrocortisone, fludrocortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, clobetasol and its nonsteroidal anti-inflammatory.
  • vitamins examples include vitamin A or a derivative thereof (eg vitamin A oil), vitamin B or a derivative thereof (eg panthenol), vitamin C or a derivative thereof, vitamin D or a derivative thereof (eg active vitamin D3), Vitamin E or a derivative thereof (for example, tocopherol acetate), vitamin K or a derivative thereof, the immunosuppressive agent is tacrolimus, cyclophosphamide, and the like, and the mucopolysaccharide is a heparin-like substance or hyaluronic acid and Examples of the salt and cAMP derivative include bucladesine sodium, fibroblast growth factor such as trafermin, and naphthoic acid derivative such as adapalene.
  • vitamin A or a derivative thereof eg vitamin A oil
  • vitamin B or a derivative thereof eg panthenol
  • vitamin C or a derivative thereof eg active vitamin D3
  • Vitamin E or a derivative thereof for example, tocopherol acetate
  • a topical composition containing a heparin-like substance or a mucopolysaccharide such as hyaluronic acid and a salt thereof is preferably exemplified.
  • the foamable composition containing a heparin-like substance has a blood coagulation suppressing action, a blood flow increasing action, a hematoma regression promoting action, a keratin water retention enhancing action and a fibroblast proliferation inhibiting action, Dry skin disease, sebum deficiency, progressive palmar keratoderma, frostbite, hypertrophic scars/keloids, pain and inflammatory diseases due to blood circulation disorder (induration and pain after injection), thrombophlebitis (including hemorrhoids) ), swelling, hematoma, tendonitis, myalgia, arthritis, and muscular torticollis after trauma (bruises, sprains, and crushes) are also suitable as a therapeutic composition.
  • Example 1 A pump former container was filled with the prepared sample according to the following prescription, and the presence or absence of foam formation at the time of discharge from the container was evaluated (Table 1, FIG. 1).
  • the samples A to I and N are polymeric surfactants.
  • each of the polymer surfactants contained in the foamable external composition of the present invention is effective as a foaming agent alone.
  • Example 2 According to the following formulation, the prepared sample was filled in a pump former container, and the presence or absence of foam formation, foam quality, foam retention time, and the presence or absence of dripping were measured (Tables 3 and 4).
  • condition A a mat of polyurethane material was used as a material close to the skin of a healthy person
  • condition B a Kim towel that assumed relatively severe dry skin was used and discharged onto it (FIGS. 2 and 3). Also, after discharging onto a mat of polyurethane material, it was tilted at about 45° C. and observed whether or not there was dripping (FIG. 4).
  • the combination of polyoxyethylene hydrogenated castor oil 60 with polyoxyethylene cetyl ether or polyoxyethylene lauryl ether does not form bubbles or has low elasticity even when formed, has a short holding time, and drips, Even when the polyhydric alcohol was combined, it was inferior in elasticity and retention time compared to the preparation using hypromellose.
  • Example 3 Using hypromellose with different viscosities, the presence or absence of foam formation was evaluated depending on the concentration. The evaluation criteria of foam quality are the same as in Example 1.
  • Bubbles were formed at a concentration of 0.2% or higher regardless of the viscosity of hypromellose.
  • Example 4 Two compositions containing a heparin-like substance at a concentration of 0.1 or 0.3% were prepared in the formulation shown in the raw material name 2 in Table 2 of Example 2, filled in a pump former container, and foamed. The presence or absence of formation, the retention time of bubbles, and the presence or absence of dripping were measured (Table 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition topique qui contient un tensioactif polymère en tant que constituant moussant et qui forme de la mousse lorsqu'elle est utilisée. Cette composition topique est utilisée pour le remplissage, par exemple, d'un récipient de type pompe à mousse ou d'un récipient de type distributeur de mousse à pression manuelle.
PCT/JP2019/049587 2018-12-19 2019-12-18 Composition topique moussante WO2020130035A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020526043A JP6781358B1 (ja) 2018-12-19 2019-12-18 起泡性外用組成物
KR1020217007588A KR102584365B1 (ko) 2018-12-19 2019-12-18 거품 발생성 외용 조성물
CN201980083678.1A CN113164511A (zh) 2018-12-19 2019-12-18 起泡性外用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018237587 2018-12-19
JP2018-237587 2018-12-19

Publications (1)

Publication Number Publication Date
WO2020130035A1 true WO2020130035A1 (fr) 2020-06-25

Family

ID=71100860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/049587 WO2020130035A1 (fr) 2018-12-19 2019-12-18 Composition topique moussante

Country Status (4)

Country Link
JP (2) JP6781358B1 (fr)
KR (1) KR102584365B1 (fr)
CN (1) CN113164511A (fr)
WO (1) WO2020130035A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
WO2023127941A1 (fr) * 2021-12-28 2023-07-06 株式会社 資生堂 Produit cosmétique de protection solaire pour pompe à agent moussant

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4937882A (fr) * 1972-08-12 1974-04-08
JP2010527332A (ja) * 2007-05-10 2010-08-12 ノイブルク スキン ケア ゲーエムベーハー ウント コー カーゲー 界面活性剤不含泡沫処方物
JP2010265241A (ja) * 2009-05-18 2010-11-25 Daizo:Kk エアゾール組成物
JP2013241371A (ja) * 2012-05-22 2013-12-05 Nisshin Kagaku Kk エアゾール組成物その使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7651990B2 (en) * 2005-06-13 2010-01-26 3M Innovative Properties Company Foamable alcohol compositions comprising alcohol and a silicone surfactant, systems and methods of use
JP4864428B2 (ja) * 2005-11-17 2012-02-01 興和株式会社 非エアゾール式のフォーム剤用組成物及び当該組成物を用いたフォーム剤
CA2807723A1 (fr) * 2010-08-13 2012-02-16 Servet Buyuktimkin Compositions moussantes de chlorite stabilise
JP2016121145A (ja) * 2014-12-24 2016-07-07 株式会社ポーラファルマ スクリーンフォーマー用の外用組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4937882A (fr) * 1972-08-12 1974-04-08
JP2010527332A (ja) * 2007-05-10 2010-08-12 ノイブルク スキン ケア ゲーエムベーハー ウント コー カーゲー 界面活性剤不含泡沫処方物
JP2010265241A (ja) * 2009-05-18 2010-11-25 Daizo:Kk エアゾール組成物
JP2013241371A (ja) * 2012-05-22 2013-12-05 Nisshin Kagaku Kk エアゾール組成物その使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HERRWERTH, S. ET AL.: "Hydroxypropyl Methylcellulose: A Unique Surface Active Polymer with Outstanding Versatility for Rinse-Off Applications", SOFW-JOURNAL, vol. 134, no. 12, 2008, pages 36 - 44 *
TANIZAKI, YOSHIHARU: "Polymeric Surface Active Agent", JOURNAL OF JAPAN OIL CHEMISTS' SOCIETY, vol. 34, no. 11, 1985, pages 73 - 78 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
WO2023127941A1 (fr) * 2021-12-28 2023-07-06 株式会社 資生堂 Produit cosmétique de protection solaire pour pompe à agent moussant

Also Published As

Publication number Publication date
JP6781358B1 (ja) 2020-11-04
KR20210106405A (ko) 2021-08-30
CN113164511A (zh) 2021-07-23
KR102584365B1 (ko) 2023-10-04
JP2020176148A (ja) 2020-10-29
JPWO2020130035A1 (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
WO2020130035A1 (fr) Composition topique moussante
US10350166B2 (en) Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
JP4828563B2 (ja) 水虫治療用外用剤
US20070292461A1 (en) Oleaginous pharmaceutical and cosmetic foam
JP2015157860A (ja) ヒトの皮膚の処置用の本質的に医薬有効成分を含まない発泡性組成物の使用
KR20060021326A (ko) 약학제, 하나 이상의 휘발성 실리콘 및 비휘발성 오일상을함유하는 분무형 조성물
JP6503303B2 (ja) 真菌感染の処置のための医薬組成物
JP2024050998A (ja) ミノキシジルを含有する外用組成物、および、ミノキシジルの析出防止方法
JP5849550B2 (ja) ステロイド性抗炎症薬含有外用剤
JP6903411B2 (ja) 外用組成物
JP5989271B1 (ja) 頭皮用外用組成物
JP6503627B2 (ja) 医薬液体組成物
JPWO2020138403A1 (ja) 皮膚外用組成物及びエアゾール剤
JP7257378B2 (ja) 水中油型エマルション
JP5909941B2 (ja) ステロイド性抗炎症薬含有外用剤
JP7045750B1 (ja) 使用感を改善したアルコール系擦り込み式手指消毒組成物
JP7329485B2 (ja) 頭皮用外用組成物
JP5565995B2 (ja) 鎮痒剤
JP2023018775A (ja) 外用組成物
JP5879837B2 (ja) ステロイド性抗炎症薬含有外用剤
KR20150085970A (ko) 하이드록시 데카노익애씨드를 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물
US20210386670A1 (en) Nanoemulsion system for transdermal delivery of pharmaceutical compositions and other active agents
JP2022008225A (ja) 皮膚外用エアゾール剤
JP2020055773A (ja) 油性外用液
KR20150085697A (ko) 피트산을 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020526043

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19897648

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19897648

Country of ref document: EP

Kind code of ref document: A1